A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
The subject of this application is N(4)-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N(2)-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine xinafoate salt, as well as inhalant formulations of the salt and a process for the preparation of the salt. This salt is probably R-343, a Syk kinase inhibitor being developed under license by Pfizer, an inhaled formulation of which is in Phase I development for the treatment of asthma.
Norman
Peter
P
Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, UK.
D000280:Administration, Inhalation; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000737:chemistry; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology; D048588:Benzoxazines / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015394:Molecular Structure; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage* / Q000737:chemistry; D013329:Structure-Activity Relationship; D000072377:Syk Kinase
D018927:Anti-Asthmatic Agents; D048588:Benzoxazines; D047908:Intracellular Signaling Peptides and Proteins; C546231:N(4)-((2,2-difluoro-4H-benzo(1,4)oxazin-3-one)-6-yl)-5-fluoro-N(2)-(3-(methylaminocarbonylmethyleneoxy)phenyl)-2,4-pyrimidinediamine; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase